Skip to content

A single-center, retrospective+prospective, observational study to understand the clinical profile and cost-effectiveness of acromegaly in a real-world clinical setting

A single-center, retrospective+prospective, observational study to understand the clinical profile and cost-effectiveness of acromegaly in a real-world clinical setting

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100049382
Enrollment
Unknown
Registered
2021-08-01
Start date
2021-10-08
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acromegaly

Interventions

Sponsors

The First Affiliated Hospital of Ji'nan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Part I of the study: 1.Patients diagnosed as acromegaly during January 1, 2011 to December 31, 2020; 2.Both male and female, regardless of age. Part II of the study: Inclusion Criteria: 1.Patients are able and willing to sign informed consent (ICF); 2.Male, female, aged 18 to 75 years (including 18 years old and 75 years old); 3.Compliance with acromegaly diagnostic criteria: (1)At least one laboratory or medical record shows that the patient is random GH >= 2.5 µg/L; (2)At least one checklist or medical record shows radiographic evidence that the patient has a pituitary tumor.

Exclusion criteria

Exclusion criteria: Part I of the study: 1.Medical records showed that the patient had been diagnosed with other concurrent malignancies or had previously been diagnosed with another malignancy and had current evidence of residual lesions. Part II of the study: 1.Ectopic GH secretion or pituitary cancer; 2.The patient is diagnosed with other complicated malignancies, or has previously been diagnosed with another malignancy, and there is currently evidence of lesion residue; 3.The patient is diagnosed with a severe acute or chronic physical or mental illness that may increase the risk associated with study participation or may interfere with the interpretation of study results, as well as any outcome that, in the investigator's judgment, makes the patient ineligible for study enrollment; 4.In the judgment of the investigator, the patient was not eligible for inclusion in the study.

Design outcomes

Primary

MeasureTime frame
clinical outcome;overall survival;

Countries

China

Contacts

Public ContactChen Zhiyong

The First Affiliated Hospital of Ji'nan University

chenzhiyong111@126.com+86 18662702387

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026